SCHEMBL30807243

SCHEMBL30807243

C=C(NC(=O)c1csc(N2C[C@@H](C)N(C(=O)OC(C)(C)C)[C@@H](C)C2)n1)C(=O)NC(=C)C(=O)OC

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.32
ACKR3 P25106 1/20 0.31
CRBN Q96SW2 1/20 0.31
MET P08581 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30807303 0.89 MAP4K4 (0.40) HRH3ACKR3CRBN
SCHEMBL30807235 0.89 MAP4K4 (0.40) HRH3ACKR3CRBN
SCHEMBL27155157 0.88 CRBN (0.33) HRH3ACKR3CRBN
SCHEMBL27155158 0.88 CRBN (0.33) HRH3ACKR3CRBN
SCHEMBL27150696 0.84 ACKR3 (0.41) HRH3ACKR3
SCHEMBL27154759 0.80 CRBN (0.33) HRH3ACKR3CRBN
SCHEMBL27154758 0.80 CRBN (0.33) HRH3ACKR3CRBN
SCHEMBL27138876 0.79 CKS1B (0.41) HRH3ACKR3
SCHEMBL30807300 0.78 BTK (0.45) ACKR3
SCHEMBL27107512 0.78 BTK (0.45) ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 US disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 US disclosed
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 EP disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX3, PRDX2 HRH3 2753/4885ACKR3 401/4885CRBN 842/4885
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 HRH3 3251/4885ACKR3 1043/4885CRBN 3084/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 HRH3 3377/4885ACKR3 974/4885CRBN 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.